Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
Last updated
72 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Sodium channel blockers

4 evidence topics · 4 sources

SCN8A-related epilepsy and neurodevelopmental disorders: global modified Delphi consensus

“Sodium channel blockers are optimal first-line treatment for GOF, severe DEE, mild/moderate DEE, and SeL(F)IE;” (opens the source at this quote in a new tab)

“sodium channel blockers are relatively contraindicated in LOF patients.” (opens the source at this quote in a new tab)

SCN2A gain-of-function phenotype: antiseizure medication regimen

“Ideally AED regimen will include sodium channel-blocking medications, such as phenytoin, lacosamide, oxcarbazepine, carbamazepine, lamotrigine, and zonisamide.” (opens the source at this quote in a new tab)

SCN8A-related disorders: cenobamate as add-on treatment

“Countable motor seizures were meaningfully reduced in 10 of 12 patients (83%).” (opens the source at this quote in a new tab)

SCN8A cenobamate evidence: study design

“In this retrospective study, the effect of cenobamate was assessed in patients with SCN8A-DEE.” (opens the source at this quote in a new tab)